ReviewInternational journal of molecular sciences2025
Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives.Drug delivery · 2026Review
- Toxicity of nanostructures in drug delivery applications.Pharmaceutical science advances · 2026Review
- The Role and Potential of Nanotechnology in Improving Solubility and Enhancing Bioavailability.Pharmaceutics · 2026Review
- A novel green synthesized ZnO-based antimicrobial nanocomposite: synergistic action, in vitro cytotoxicity, and molecular docking studies of ceftazidime, metformin, and chitosan against multidrug-resistant Salmonella enterica.Microbial cell factories · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles (NPs) have significantly changed the field of drug delivery, offering control over pharmacokinetics, biodistribution, and targeted therapy. Among these, ultrasmall nanoparticles (USNPs) with sizes of approximately 5-15 nm have garnered significant interest due to their unique physicochemical properties, including enhanced cellular uptake, deeper tissue penetration, and prolonged systemic circulation. This review explores the fundamental principles governing sub-15 nm nanoparticles, their classification, and their distinctive advantages in pharmaceutical applications. Various types of nanoparticles, including polymeric, lipid-based, metallic, and carbon-based nanosystems, are examined in the context of drug delivery in cancer therapy. We detail how sub-15 nm polymeric nanoparticles (PNPs) are emerging as transformative drug delivery platforms for cancer therapy. The impact of nanoparticle size, surface modifications, and biocompatibility on therapeutic performance is critically analyzed. Furthermore, we discuss emerging applications of these ultrasmall nanoparticles in cancer therapy, neurological disorders, vaccine delivery, and imaging. Despite their promise, key challenges such as stability, aggregation, toxicity, and regulatory concerns remain significant hurdles for clinical translation. This review provides insights into the potential of 5-15 nm nanoparticles to reshape modern drug delivery and highlights future directions for research and development in this rapidly evolving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.